Zacks Investment Research on MSN
Healthcare ETFs to buy as JNJ beats the market with a 25% YTD surge
Johnson & Johnson JNJ, a healthcare behemoth with a market cap exceeding $600 billion and a portfolio spanning pharmaceuticals and medical devices, has delivered a stellar year-to-date surge of ...
Johnson & Johnson (JNJ) is expected to report upbeat second quarter results on July 15, before market open, with analysts expecting the firm to post a ~3% Y/Y jump in earnings. Wall Street sees ...
Johnson & Johnson (JNJ) delivers Q2 earnings July 15. Wall Street projects $2.86 EPS, $25.02B revenue. See what analysts ...
Johnson & Johnson is the easiest healthcare name to evaluate on the board heading into its July 15 earnings release, and the ...
Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still ...
This healthcare giant is on a serious run, but for investors arriving now, the question is whether the price of admission ...
The healthcare giant raised its outlook for the year, yet the market is holding back its reward, creating a tense waiting ...
Johnson & Johnson (NYSE: JNJ) recently released its Q1 earnings, surpassing analyst estimates on both revenue and earnings. The company posted adjusted earnings of $2.77 per share on revenue of $21.9 ...
CHONGQING, CHINA - JULY 13: In this photo illustration, a smartphone displaying the logo of Johnson & Johnson (NYSE: JNJ), a leading American multinational corporation known for pharmaceuticals, ...
Johnson & Johnson (Symbol: JNJ) has been named as a Top 25 ''Dividend Giant'' by ETF Channel, with a whopping $57.05B worth of stock held by ETFs, and above-average ''DividendRank'' statistics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results